Nuclear to Cytoplasmic Transport is a Druggable Dependency in MYC-Driven Hepatocellular Carcinoma. Deutzmann A, Sullivan DK, Dhanasekaran R, Li W, Chen X, Tong L, Mahauad-Fernandez WD, Bell J, Mosley A, Koehler AN, Li Y#, Felsher DW. Nature Communications, 2024;15(1):963. #co-corresponding author. https://www.nature.com/articles/s41467-024-45128-y
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters. Liu, Y., Azizian, N. G., Sullivan, D. K. & Li Y. Nature Communications. 2022 Nov 17;13(1):7047. https://www.nature.com/articles/s41467-022-34890-6
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells. Du, R, Sullivan, DK, Azizian, NG, Liu, Y & Li, Y 2021, , BMC Cancer, vol. 21, no. 1, 237. https://doi.org/10.1186/s12885-021-07967-6
Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo. Li, Y 2020, , Journal of Proteome Research. https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00666
XPO1-dependent nuclear export as a target for cancer therapy. Azizian, NG, Azizian, NG, Li, Y & Li, Y 2020, , Journal of Hematology and Oncology, vol. 13, no. 1, 61. https://doi.org/10.1186/s13045-020-00903-4
Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. Liu, Y, Azizian, NG, Dou, Y, Pham, LV & Li, Y 2019, , Journal of Hematology and Oncology, vol. 12, no. 1. https://doi.org/10.1186/s13045-019-0803-9
Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Li, Y, Thomas, D, Deutzmann, A, Majeti, R, Felsher, DW & Dill, DL 2019, , Scientific Reports, vol. 9, no. 1, pp. 16775. https://doi.org/10.1038/s41598-019-53290-3
Rational targeted therapeutics for double-hit lymphoma. Azizian, NG, Liu, Y, Pham, LV & Li, Y 2019, , International Journal of Hematologic Oncology, vol. 8, no. 3, pp. IJH19. https://doi.org/10.2217/ijh-2019-0009